This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
Facts about Proteasome activator complex subunit 2.
.
Human | |
---|---|
Gene Name: | PSME2 |
Uniprot: | Q9UL46 |
Entrez: | 5721 |
Belongs to: |
---|
PA28 family |
11S regulator complex beta subunit; 11S regulator complex subunit beta; Activator of multicatalytic protease subunit 2; MCP Activator; MCP activator, 31-kD subunit; PA28 Activator beta Subunit; PA28b; PA28betacell migration-inducing protein 22; proteasome (prosome, macropain) activator subunit 2 (PA28 beta); Proteasome activator 28 subunit beta; proteasome activator 28-beta; proteasome activator complex subunit 2; proteasome activator hPA28 subunit beta; PSME2; REGbeta; REG-beta
Mass (kDA):
27.402 kDA
Human | |
---|---|
Location: | 14q12 |
Sequence: | 14; NC_000014.9 (24143365..24146646, complement) |
One of the most commonly tested genes in humans is the PSME2 gene. It has the highest level of human DNA. Therefore, it is crucial to monitor for changes in its expression in humans. PSME2 has many other uses than disease prevention and medical research. Its potential to prevent cancer and cardiovascular disease is one of them. PSME2 can also be involved in the development many other diseases like Alzheimer's.
The PSME2 gene encodes PSME2, also known as proteasome activate complex subunit 2. Its increased expression leads to an increase in levels of inflammatory proteins like CXCL9 or BLys that are critical components of the tumor microenvironment. PSME2 is expressed in cells in many tissues, including the liver, kidney, and intestine. This gene is associated with several types of cancer.
Human ccRCC often has higher levels of PSME2. It was also associated negatively with prognosis among ccRCC-patients. The tumor tissue was strongly associated with the WGCNA network's brown module. PSME2 may therefore be an important prognostic sign for the disease. Further, PSME2 expression was related to T and M stages.
PSME2 has been linked to tumor invasion and prognostic factors. A recent study used short interferingRNA to target PSME2 to analyze PSME2 expression in human ccRCC tissues and renal cancer cell lines. Transfection with a PSME2-specific SiRNA reduced tumor cell invasion and increased autophagy. It also inhibited BNIP3-mediated Autophagy. It could be a promising therapeutic target for ccRCC.
PSME2 expression was increased in bladder urothelial cancer, breast invasive carcinoma, endocervical carcinomama, and head & neck squamous cells carcinoma. PSME2 expression was higher in paraganglioma, uterine invasive carcinoma, and pheochromocytoma. PSME2 expression is associated with OS (DSS), PFS (PFS), and PFH. This suggests that it may be a potential therapeutic target.
In another study, PSME2 was expressed in kidney tumor cells more than in the surrounding tissue. Experiments using renal carcinoma cell lines produced similar results. These results were consistent for the bioinformatics analyses. These results suggest that PSME2 may play important roles in kidney cancer. PSME2 gene expression is widespread in normal tissues including HK-2.786-O cell lines and CAKI-1 cells.
PSME2 is linked to the TNF-kB signaling pathway as well as the cytokine/cytokine receptor interplay. It is also associated with autophagy-animal. These results suggest that PSME2 could be involved in autophagy of tumor tissues. It is also linked to NF-kB signaling. The study highlighted the importance PSME2 to cancer research.
The PSME2 gene belongs to the proteasome group and is expressed in kidney. The PSME2 gene is associated with several diseases, including prostate cancer, uterine fibroids, renal clear cell carcinoma (KIRC), and uterine fibroids. Among these diseases, PSME2 is particularly important for detecting uterine fibroids. Several different methods are available to determine the presence of PSME2 in the kidney.
The PSME2 gene has been linked to TNF signaling pathway interaction and cytokine -cytokine receptor interaction. PSME2 is implicated in many aspects of cancer including tumor growth, immune cells, cytokine release, and cytokine secretion. PSME2 can play a key role in cancer therapy and diagnosis. It may also serve as a biomarker to ccRCC.
The PSME2 gene is highly expressed in ccRCC cells. Although overexpression of PSME2 is not associated with cell proliferation it may be related to autophagy or the tumor microenvironment. It was possible to determine the level of BNIP3 using siPSME2. Knockdown experiments and rescue experiments have been used to identify the function of PSME2, and future research should focus on this gene.
PSME2 is a highly specific and valuable gene in the field of cancer. It is involved the autophagy process, which is the elimination of polyubiquitinated proteins. Its overexpression promotes invasion of renal carcinoma cells. It is also useful in studying prostate cancer, ovarian cancer, and rhabdomyoid tumors. There are some limitations and potential uses for PSME2, but there are many other applications for PSME2.
While PSME2 expression is generally low in the tumor tissues, it has been shown to increase in renal cancer and other types of kidney cancer. PSME2 expression also occurs in cell lines derived form normal organs, such HK-2-786O, CAKI-1, and HK-2-786O. The study also revealed an association with DSS/PFS. However, further research is needed to determine the precise role of PSME2 in identifying renal cancer.
The PSME2 protein gene has 3,868 functions that are associated with biological entities. It is also highly expressed in human cancers. We will examine gene infographics that are based on PSME2 gene activity to better understand the role of PSME2 for a variety of human cancers. We also explore the relationship between PSME and m6A related genes. This marker allows us the identification of the most common mutations that cause cancer. Additionally, gene infographics can be created based off the PSME2 genome.
The PSME gene family is involved in cell cycle regulation, NIK/NFKB pathway, DNA repair and immune response. These genes were also involved in cell cycle regulation and cellular response to oxygen levels and in regulating the activity of the proteasome. PSME genes were previously believed to be involved in tumor development and progression. These genes are important in tumorigenesis, but they are not the only ones.
This study used data from TC3A to visualize PSME gene expression. PSME genes were found enriched for expression in various types of cancers. Using this data, we mapped the distribution of PSME gene expression in gastric cancer by using a grid violin plot. A visual summary oncoprint based on PSME gene expression can also be seen in this plot.
This gene infographics database lists gene expression levels in the PSME2 genes and OS, FPS (PPS), PSME3 and PSME2. The study's data is based upon a large number of prospective cancer trials. The Kaplan-Meier plotter was used to adjust the P value to 0.05. The bold values indicate statistical significance. OS, FPS and PS are acronyms for overall survival.
PMID: 10199920 by McCusker D., et al. Organization of the genes encoding the human proteasome activators PA28alpha and beta.
PMID: 7789512 by Ahn J.Y., et al. Primary structures of two homologous subunits of PA28, a gamma- interferon-inducible protein activator of the 20S proteasome.